Americas Gastrointestinal Drugs Market is Expected to Reach 59.3 billion by 2023 at CARG of 6% during Forecast Period of 2017-2023 :

Pune, India, June, 2017 /MRFR Press Release/- Market research future has a half cooked research report on Americas gastrointestinal drugs market. The Americas gastrointestinal drugs market is growing at an average rate and is expected show the similar trend during forecast period.


Market Highlights


Gastrointestinal (GI) drug market involves pharmacological and non-pharmacological treatment. Different types of gastrointestinal disorder includes constipation, diverticular diseases, colon polyps, irritable bowel syndrome, and many more. Many of the GI diseases can be prevented and minimized by maintaining a healthy lifestyle and balanced diet. The factors like increasing prevalence of increasing of various different gastrointestinal disease, increasing elderly population, technological advances are responsible for driving gastrointestinal market. Whereas unavailability of treatment for some of gastro intestinal diseases may be responsible for hampering the market growth.


Americas Market Player for Gastrointestinal Drugs


There are players in global and local gastrointestinal drug market:  AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke Pharma (US), Valent Pharmaceuticals(US)


AstraZeneca has entered into an agreement with gastroenterology specialist Tillotts Pharma for Entocort. Entocort is a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis. The medicine is now available in across 40 countries, the product sales gained $53 million outside the US in 2014. The agreement shows that Tillotts will pay AstraZeneca $215 million on completion of the transaction to acquire the rights to sell and develop Entocort capsules and formulations outside the US.


Janssen Biotech Inc., the company received FDA approval for the Remicade medicine which is used to treat pediatric ulcerative colitis in 2011. Since then company has a product for pediatric gasrtrointestinal drugs.


GlaxoSmithKline Plc, has a products Eno available in Latin America and Asian market. The product is doing extremely well in these regions. The product is available in various flavor. The product is an antacid. The product is also available in different forms. Company has vast range of products in consumers based and in prescription based products. It hold very strong presence worldwide.


Bayer AG, the company has a wide range of the gastrointestinal products. One of the product Iberogast is herbal product which give relief from multiple problems of gastrointestinal system.


Figure 1           Players for Gastrointestinal Drugs Market Share, 2016

Americas Gastrointestinal Drugs Market--



Segmentation:
The Segmentation for Americas Gastrointestinal Drug market is done on the basis of drug category, route of administration, disease type, and by end users. On the basis of the drug category the market is segmented into Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory, Antiemetic and others. Further the Acid Neutralizers are sub-segmented into Antacid, H2 antagonists, Proton Pump Inhibitors and others. On the basis of route of administration the segments includes oral, parental and rectal. On the basis of disease type, market is segmented into gastro-esophageal reflux diseases, inflammatory bowel diseases and others. The inflammatory diseases are further segmented into two types Crohn’s diseases and ulcerative disease. The Ulcerative diseases are further sub segmented into ulcerative protitis, proctosigmoiditis, left sided colitis, pancolitis and acute severe ulcerartive colitis. The end user segment includes hospital pharmacies, retail pharmacies and others.


Access Complete Report at https://www.marketresearchfuture.com/reports/americas-gastrointestinal-drugs-market-583


About Market Research Future:


At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.


MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.


In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.


Contact:


Akash Anand,


Market Research Future


Office No. 528, Amanora Chambers


Magarpatta Road, Hadapsar,


Pune - 411028


Maharashtra, India


+1 646 845 9312


Email: akash.anand@marketresearchfuture.com